A. A. Schwarzinger-m, D. J. Dufouil-c, and R. K. Tzourio-c, Vers une prévention de la démence?, Rev Neurol, vol.160, pp.256-260, 2004.

B. D. Schneider-j, W. R. Bienias, and . Arnold-s, Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function, Arch Neurol, vol.61, pp.378-384, 2004.

C. C. Farrell-d and G. R. , Long term donepezil treatment in 565 patients with Alzheimer' s disease (AD 2000): randomised double-blind trial, Lancet, vol.363, pp.2105-2115, 2004.

C. J. Cole-g, Alzheimer disease, JAMA, vol.287, pp.2335-2338, 2002.

D. J. Goulley-f, P. J. Bourdeix-i, and . Barberger-gateau-p, Utilisation de la rivastigmine en pratique médicale courante chez des patients ambulatoires présentant une maladie d' Alzheimer, Rev Neurol, vol.158, pp.807-812, 2002.

D. J. Helmer-c and . Dubois-b, La maladie d' Alzheimer, un problème de santé publique : oui ... une priorité?, Rev Neurol, vol.158, pp.311-315, 2002.

D. B. , T. H. Micron-a, . Deweer-b, B. M. Besson-j, and C. B. , Les déficits cognitifs de la maladie d' Alzheimer, pp.183-197, 1997.

E. J. Dournaud-p, . Krzywkowski-p, B. M. Besson-j, and C. B. , Atteintes neurochimiques de la maladie d' Alzheimer et recherche de modèles animaux, pp.53-81, 1997.

F. Arlow-m, Pharmacokinetic profiles of current therapies for Alzheimer' s disease : implications for switching to galantamine, Clin Ther, vol.23, pp.13-24, 2001.

G. D. Provenzano-g, R. T. Mc, and . Mastey-v, Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease, J Am Geriatr Soc, vol.51, pp.937-944, 2003.

H. D. Goldlist-b, . Naglie-g, and . Patterson-c, Comparison studies of cholinesterase inhibitors for Alzheimer' s disease, Lancet neural, vol.3, pp.622-626, 2004.

I. B. and R. A. Hofman-a, Nonsteroidal antiinflammatory drugs and the risk of Alzheimer' s disease, N Engl J Med, vol.345, pp.1515-1521, 2001.

J. H. Zornberg-g, J. S. Seshadri-s, and . Drachman-d, Statins and the risk of dementia, Lancet, vol.356, pp.1627-1631, 2000.

K. M. Vi, La vie quotidienne du malade d 'Alzheimer, Editions Doin, p.79, 1995.

L. R. , M. N. Moride-y, . G. Miremont-salame, and . Begaud-b, Benzodiazepine utilization patterns in Alzheimer's disease patints, Pharmacoepidemiol Drug Sa, vol.12, pp.511-515, 2003.

M. E. Laurier-grymonprez and . C. Baisset-mouly, Profils mnésiques différents dans la démence à corps de Lewy et la maladie d' Alzheimer débutante, Rev Neurol, vol.159, pp.762-766, 2003.

M. C. Rosenberg-r, Memory loss, when is it Alzheimer's disease?, JAMA, vol.279, pp.1689-1690, 1998.

R. M. Peskind-e, . Truyen-l, and . Kersha-w-p, The cognitive benefits of galantamine are sustained for at least 36 months, a long term extension trial, Arch Neurol, vol.61, pp.252-256, 2004.

R. A. Latour-f and . Lenoir-h, Prise en charge thérapeutique de la démence, EMC Méd, vol.2, pp.145-151, 2005.

R. R. Adityanjee and D. M. , Efficacity and tolerability of memantine in the treatment of dementia, Am J Geriatr Pharmacother, vol.2, pp.303-312, 2004.

S. E. Scheltens-p and . Feldman-h, Treatment of Alzheimer' s disease: current status and new perspectives, Lancet neural, vol.2, pp.539-547, 2003.

S. B. Zolnouni-p and . Nunez-m, Efficacity of donepezil in early-stage Alzheimer disease, Arch Neurol, vol.61, pp.1852-1856, 2004.

S. K. Holden-k, Pharmacological treatment of neuropsychiatrie symptoms of dementia, JAMA, vol.293, pp.596-608, 2005.

S. S. Kaul-c, Dementia of Alzheimer's disease and other neurodegenerative disorders: memantine, a new hope, PharmacolRes, vol.51, pp.1-17, 2005.

T. P. Farlow-m, G. S. Grossberg-g, and D. S. Mc, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil, JAMA, vol.291, pp.317-324, 2004.

T. L. Gibbons-l and C. S. Mc, Exercise plus behavioral management in patients with Alzheimer disease, JAMA, vol.290, pp.2015-2022, 2003.

T. J. Portet-f-bogoussla, . J. Vsky, M. M. Leger-j, and . Démences, Démences à corps de Lewy, Editions Doin, pp.193-201, 2002.

T. N. Hobl, Y. J. , and M. S. , Efficacity of cholinesterase inhibitors in the treatment of neuropsychiatrie symptoms and functional impairment in Alzheimer disease, JAMA, vol.289, pp.210-216, 2003.

W. B. and N. A. Gill-m, A review of rivastigmine: a reversible cholinesterase inhibitor, Clin Ther, vol.25, pp.1634-1653, 2003.

Z. P. and A. J. Khachaturian-a, Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements, Arch Neural, vol.61, pp.82-88, 2004.

Z. G. Gargiulo-a and . Lamenza-f, The management of psychogeriatric patient, Arch Gerontol Geriatr, vol.9, pp.465-470, 2004.

. Fascicule-interactions-médicamenteuses and . Vidal, 79-Interactions médicamenteuses : nouveautés 2002, Rev Prescrire, vol.22, pp.436-439, 2002.

!. Qu, !ltc 4'lll' lu date ~imp!~c d..'m.1j<:>tud'fali? ___________ _ 2

. Je and . ~. Yb, 1~r t1U.:CS'lttti?!ll §ll:lf n.'t!df<Jiil ni): llGU!i tl\li!\'l)!iiii

%. Ville, 4'1.?Ïl '! lt Qud t1ti 1<i nom th1 daus l'lltquc! am xi!li1